

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C12N 15/86, 9/00, 9/22, 7/04, 5/10 //</b> <b>A61P 31/18</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/55341</b> <b>(43) International Publication Date:</b> 21 September 2000 (21.09.00)
<b>(21) International Application Number:</b> PCT/GB00/01002 <b>(22) International Filing Date:</b> 17 March 2000 (17.03.00)  <b>(30) Priority Data:</b> 9906177.2                      17 March 1999 (17.03.99)                      GB  <b>(71) Applicant (for all designated States except US):</b> OXFORD BIOMEDICA (UK) LIMITED [GB/GB]; Medawar Centre, The Oxford Science Park, Robert Robinson Avenue, Oxford OX4 4GA (GB).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> UDEN, Mark [GB/GB]; Flat 2, Finsbury Park, 17 Sommerfield Road, London N4 2JN (GB). MITROPHANOUS, Kyriacos [GR/US]; 85 Warwick Street, Oxford OX4 1SZ (US).  <b>(74) Agents:</b> MASCHIO, Antonio et al.; D Young & Co., 21 New Fetter Lane, London EC4A 1DA (GB).		<b>(81) Designated States:</b> AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> ANTI-VIRAL VECTORS  <b>(57) Abstract</b>  A viral vector production system is provided which system comprises: (i) a viral genome comprising at least one first nucleotide sequence encoding a gene product capable of binding to and effecting the cleavage, directly or indirectly, of a second nucleotide sequence, or transcription product thereof, encoding a viral polypeptide required for the assembly of viral particles; (ii) a third nucleotide sequence encoding said viral polypeptide required for the assembly of the viral genome into viral particles, which third nucleotide sequence has a different nucleotide sequence to the second nucleotide sequence such that said third nucleotide sequence, or transcription product thereof, is resistant to cleavage directed by said gene product; wherein at least one of the gene products is an external guide sequence capable of binding to and effecting the cleavage by RNase P of the second nucleotide sequence. The viral vector production system may be used to produce viral particles for use in treating or preventing viral infection.		